Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eton Pharmaceutcials Inc (ETON)

Eton Pharmaceutcials Inc (ETON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 327,461
  • Shares Outstanding, K 26,051
  • Annual Sales, $ 31,640 K
  • Annual Income, $ -940 K
  • EBIT $ -5 M
  • EBITDA $ -4 M
  • 60-Month Beta 1.39
  • Price/Sales 10.11
  • Price/Cash Flow 3,842.54
  • Price/Book 19.85

Options Overview Details

View History
  • Implied Volatility 63.91% ( +0.48%)
  • Historical Volatility 75.05%
  • IV Percentile 9%
  • IV Rank 12.20%
  • IV High 342.43% on 05/07/24
  • IV Low 25.22% on 02/13/24
  • Put/Call Vol Ratio 39.68
  • Today's Volume 895
  • Volume Avg (30-Day) 164
  • Put/Call OI Ratio 0.06
  • Today's Open Interest 3,510
  • Open Int (30-Day) 3,166

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.04
  • Number of Estimates 1
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year -0.09
  • Growth Rate Est. (year over year) +55.56%

Price Performance

See More
Period Period Low Period High Performance
1-Month
10.20 +23.24%
on 11/21/24
13.98 -10.09%
on 12/02/24
+2.14 (+20.52%)
since 11/20/24
3-Month
5.36 +134.51%
on 09/23/24
13.98 -10.09%
on 12/02/24
+7.15 (+131.92%)
since 09/20/24
52-Week
3.03 +314.85%
on 04/17/24
13.98 -10.09%
on 12/02/24
+8.03 (+176.87%)
since 12/20/23

Most Recent Stories

More News
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)

ETON : 12.57 (+2.36%)
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial

ETON : 12.57 (+2.36%)
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

Eton Pharmaceuticals appointed Ipek Erdogan-Trinkaus as Chief Commercial Officer, leveraging her extensive pharmaceutical sales and marketing expertise.Quiver AI SummaryEton Pharmaceuticals, Inc. has appointed...

ETON : 12.57 (+2.36%)
Eton Pharmaceuticals Appoints Ipek Erdogan-Trinkaus as Chief Commercial Officer

ETON : 12.57 (+2.36%)
Eton Pharma - Small Cap That's Climbing

Summary Eton Pharmaceuticals (ETON) has shown exceptional price appreciation, gaining 224.93% since a Trend Seeker buy signal on 7/17, supported by strong technical indicators. The company focuses on developing...

ETON : 12.57 (+2.36%)
Eton Pharmaceuticals Acquires U.S. Rights to Amglidia® for Neonatal Diabetes Treatment Following EMA Approval

Eton Pharmaceuticals acquires U.S. rights to Amglidia, approved in Europe for neonatal diabetes mellitus, aiming for 2026 FDA submission.Quiver AI SummaryEton Pharmaceuticals has acquired the U.S. rights...

ETON : 12.57 (+2.36%)
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)

ETON : 12.57 (+2.36%)
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

ETON : 12.57 (+2.36%)
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)

ETON : 12.57 (+2.36%)
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

ETON : 12.57 (+2.36%)

Business Summary

Eton Pharmaceuticals Inc. operates as a development stage biotechnology company. Its product pipeline consists of DS-300, EM-100, DS-100, DS-200, ET-103, ET-101, ET-102 and CT-100 which are in clinical stage. Eton Pharmaceuticals Inc. is based in Deer Park, Illinois.

See More

Key Turning Points

3rd Resistance Point 14.30
2nd Resistance Point 13.80
1st Resistance Point 13.18
Last Price 12.57
1st Support Level 12.06
2nd Support Level 11.56
3rd Support Level 10.94

See More

52-Week High 13.98
Last Price 12.57
Fibonacci 61.8% 9.80
Fibonacci 50% 8.51
Fibonacci 38.2% 7.21
52-Week Low 3.03

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar